clinical trial · NCT00647855
Fasting Study of Levothyroxine Sodium Tablets 300 μg to Synthroid® Tablets 300 μg
HealthyLevothyroxine Sodium Tablets 300 μgSynthroid® Tablets 300 μg
brief summary
The objective of this study was to investigate the bioequivalence of Mylan's levothyroxine sodium 300 μg tablets to Abbott's Synthroid® 300 μg tablets following a single 600 μg (2 x 300 μg) dose administered in healthy volunteers under fasting conditions. Single-dose pharmacokinetic parameters for baseline corrected total L-thyroxine and non-baseline corrected total L-triiodothyronine were calculated using noncompartmental techniques.
started
May 1, 2003
primary completion
Jun 1, 2003
completion
Jun 1, 2003
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Levothyroxine Sodium Tablets (300 μg; Mylan) to Synthroid® Tablets (300 μg; Abbott) in Healthy Volunteers.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol